^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

THF dehydrogenase inhibitor

1d
Hepatic methotrexate-associated lymphoproliferative disease: a case report and literature review. (PubMed, Surg Case Rep)
MTX-LPD can occur in the liver. Clinician should suspect hepatic MTX-LPD when a liver mass is detected in patient who had been treating with MTX for RA.
Review • Journal
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
methotrexate
2d
Identification of Genomic Biomarkers of Disease Progression and Survival in Primary CNS Lymphoma. (PubMed, Blood Adv)
We applied targeted next-generation sequencing for detection of recurrent single nucleotide variants, copy number alterations and zygosity abnormalities in diagnostic specimens from 78 PCNSL patients treated with a standard methotrexate-based regimen, to identify prognostically significant molecular subgroups...These genomic aberrations identify a high-risk molecular subgroup that may inform risk stratification in PCNSL. Further elucidation of the mechanisms of therapeutic resistance associated with the high-risk genetic phenotype is requisite to facilitate precision medicine and progress in therapy.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • ETV6 (ETS Variant Transcription Factor 6)
|
TP53 mutation
|
methotrexate
3d
Intrapulmonary Biphasic Mesothelioma Misdiagnosed as Adenocarcinoma: Case Report and a Potential Diagnostic Pitfall. (PubMed, Onco Targets Ther)
The patient was treated with a chemotherapy regimen of pemetrexed and carboplatin. Mesothelioma with predominantly intrapulmonary growth is extremely rare and poses a diagnostic pitfall. For this entity, subtle morphological features, selection of immunohistochemical markers, and electron microscopy are of great significance for definite diagnosis.
Journal
|
WT1 (WT1 Transcription Factor) • CD34 (CD34 molecule) • NKX2-1 (NK2 Homeobox 1) • NAPSA (Napsin A Aspartic Peptidase)
|
TTF1 negative
|
carboplatin • pemetrexed
3d
Evaluation of UCP1162, a potent propargyl-linked inhibitor of dihydrofolate reductase with potential application to cancer and autoimmune disease. (PubMed, Biochem Pharmacol)
Here we examine the biochemical and cellular effects of a propargyl linked, non-classical antifolate that shows exceptional potency and resilience in the background of methotrexate resistance, UCP1162...Leucovorin suppressed the cellular effects of UCP1162, consistent with UCP1162 working as an antifolate...Long-term exposure to UCP1162 resulted in static culture expressing stem cell genes (CD34, ABCG2, ABCB1), adaptive genes (TCN2, CDKN1A), and genes that might serve as therapeutic targets (TPBG/5T4, TNFRSF10A, ACE). These findings suggest that UCP1162 is a unique tool for studying cellular responses to long-term antifolate treatment and holds promise as a lead compound capable of overcoming some forms of antifolate resistance.
Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • TPBG (Trophoblast Glycoprotein) • CD34 (CD34 molecule) • TNFRSF10A (TNF Receptor Superfamily Member 10a) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
methotrexate • leucovorin calcium
6d
Intrathecal Pemetrexed for Leptomeningeal Metastasis (clinicaltrials.gov)
P1/2, N=34, Completed, The First Hospital of Jilin University | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Mar 2024
Trial completion • Trial completion date
|
pemetrexed • dexamethasone injection
11d
Combination of Methotrexate and Resveratrol Reduces Pro-Inflammatory Chemokines in Human THP-1 Cells. (PubMed, J Inflamm Res)
The combination of MTX and resveratrol effectively attenuated pro-inflammatory activity in THP-1 cells, as evidenced by the downregulation of mRNA and chemokine expression. These findings suggest that the synergistic effects of MTX and resveratrol hold promise for enhancing cancer therapeutics.
Journal
|
CXCL10 (Chemokine (C-X-C motif) ligand 10) • CCL4 (Chemokine (C-C motif) ligand 4) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL3 (C-C Motif Chemokine Ligand 3)
|
methotrexate
13d
Computational identification of PDL1 inhibitors and their cytotoxic effects with silver and gold nanoparticles. (PubMed, Sci Rep)
Their conjugation with the drugs Irinotecan, Imatinib, and Methotrexate was also confirmed using UV-Vis, FTIR, and Dynamic light scattering (DLS). The result of the methylthiazol tetrazolium (MTT) assay showed that conjugated AgNPs and AuNPs with Irinotecan had a higher toxic effect on the A549 cancer cell line than AgNPs and AuNPs conjugated with Imatinib. This study provides a promising avenue for further investigation and development of nanoparticle-drug conjugates as a potential cancer immunotherapy strategy.
Journal
|
PD-L1 (Programmed death ligand 1)
|
imatinib • irinotecan • methotrexate
14d
New trial
|
Epidaza (chidamide) • Folotyn (pralatrexate)
18d
Analysis of Therapeutic Efficacy and Adverse Prognostic Factors of Secondary Central Nervous System Lymphoma (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
HD-MTX combined with TMZ as the first-line strategy may improve patient prognosis, and early application of gene sequencing is beneficial for evaluating prognosis.
Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • KMT2D (Lysine Methyltransferase 2D) • CD79B (CD79b Molecule) • PIM1 (Pim-1 Proto-Oncogene) • BTG2 (BTG Anti-Proliferation Factor 2) • TBL1XR1 (TBL1X Receptor 1)
|
HER-2 mutation • PIM1 mutation
|
methotrexate IV
19d
The impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity. (PubMed, EBioMedicine)
This study provides a mechanistic rationale to clinical evidence correlating the poor outcome of patients with mesothelioma and with eosinophil-derived CLC-P/Gal10, opening new prospects for intervention in this fatal solid tumour.
Journal
|
LGALS1 (Galectin 1)
|
cisplatin • pemetrexed
21d
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis (clinicaltrials.gov)
P2, N=16, Recruiting, Wake Forest University Health Sciences | Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Oct 2024 --> Mar 2025
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR negative • HER-2 negative + AR positive + ER positive • HER-2 negative + PGR positive
|
methotrexate IV
21d
Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors (clinicaltrials.gov)
P2, N=50, Active, not recruiting, Yancheng First People's Hospital | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Jun 2023 --> Dec 2023
Enrollment closed • Trial completion date • Trial primary completion date • Metastases
|
methotrexate
23d
Curcumin and Methotrexate: A Promising Combination for Osteosarcoma Treatment via Hedgehog Pathway Inhibition. (PubMed, Int J Mol Sci)
A chemotherapy regimen includes a combination of high-dose Methotrexate (MTX), doxorubicin, and cisplatin...CUR and MTX combined determined a β-Catenin decrease and a trend toward reducing NF-kB and matrix metalloproteinases (MMP-2 and MMP-9). Our findings suggest CUR as a support to OS treatment, improving outcomes and reducing the adverse effects of current therapies.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • PTCH1 (Patched 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • GLI1 (GLI Family Zinc Finger 1) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • MMP9 (Matrix metallopeptidase 9) • GLI2 (GLI Family Zinc Finger 2)
|
GLI2 overexpression
|
cisplatin • doxorubicin hydrochloride • methotrexate • methotrexate IV
24d
Chronic stress-mediated dysregulations in inflammatory, immune and oxidative circuitry impairs the therapeutic response of methotrexate in experimental autoimmune disease models. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
Here, in this study, we investigated the detrimental impact of an 8-week chronic unpredictable stress (CUS) protocol on the progression of arthritis and psoriasis using collagen-induced arthritis (CIA) and imiquimod (IMQ)-induced psoriasis rat models, respectively. Moreover, the therapeutic efficacy of MTX was notably reduced in stressed rats compared to non-stressed, underscoring the detrimental effects of chronic stress on treatment outcomes. Taken together, our results emphasize the importance of considering chronic stress as a critical factor in the management of autoimmune diseases.
Journal
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha)
|
methotrexate • Zyclara (imiquimod)
24d
Association of SLC19A1 Gene Polymorphisms and Its Regulatory miRNAs with Methotrexate Toxicity in Children with Acute Lymphoblastic Leukemia. (PubMed, Curr Issues Mol Biol)
Our results indicate that there is a statistically significant correlation between the rs1131596 SLC19A1 polymorphism and the development of MTX-induced hepatotoxicity (p = 0.03), but there is no significant association between any of the studied polymorphisms and mucositis or other side effects, such as nausea, emesis, diarrhea, neutropenia, skin rash and infections. In addition, when genotype TT of rs1131596 and genotype AA of rs56292801 are both present in a patient then there is a higher risk of developing severe hepatotoxicity (p = 0.0104).
Journal
|
SLC19A1 (Solute Carrier Family 19 Member 1)
|
methotrexate
25d
Huangqi Glycoprotein improves myocardial injury in rats with adjuvant arthritis by interfering with lncRNA GAS5/miR-21/TLR4 signaling axis to inhibit pyroptosis (PubMed, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi)
Methods SD rats were randomized into normal control, model, methotrexate (MTX) and HQGP groups, with 6 rats in each group...In myocardial tissue, the expression of GAS5 increased significantly, the expression of miR-21 decreased significantly, the release of LDH, the mRNA and protein levels of TLR4, NF-κB p65, caspase-1 and NLRP3 decreased significantly, and the mRNA expression of GSDMD reduced while the protein level significantly reduced. Conclusion HQGP improves myocardial injury in AA rats by inhibiting miR-21/TLR4 signalling through up-regulation of lncRNA GAS5, inhibiting pyroptosis, and reducing pro-inflammatory cytokine expression.
Preclinical • Journal • IO biomarker
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MIR21 (MicroRNA 21) • IL18 (Interleukin 18) • NLRC5 (NLR Family CARD Domain Containing 5) • GAS5 (Growth Arrest Specific 5) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • GSDMD (Gasdermin D)
|
IL6 expression
|
methotrexate
28d
An Impressive Response to Zoldronic Acid Treatment for Chronic Recurrent Multifocal Osteomyelitis: A Case Report. (PubMed, J Investig Med High Impact Case Rep)
Data on the use of zoledronic acid (ZA) in juvenile CRMO are scarce...The patient's condition stayed stable while taking naproxen (20 mg/kg/day) and methotrexate (10 mg/week) for 1.5 years until he experienced right elbow pain, swelling, no overlying skin erythema, and a restricted range of motion...Non-steroidal anti-inflammatory drugs and methotrexate were initially effective in treating our patient's condition, but a recurrence necessitated treatment modification. To the best of our knowledge, this case is the first documented instance of the use of ZA in CRMO in Iraq and Arab nations.
Journal
|
CRP (C-reactive protein)
|
methotrexate • zoledronic acid
28d
Radiation Toxicity in MDA5+ and PL7-Positive Dermatomyositis: Heightened Risk in Autoimmune Subtypes. (PubMed, Int J Part Ther)
He received 4 cycles of pemetrexed/cisplatin with proton therapy (PT) delivered halfway through for a bronchial stump positive margin. Immunosuppressive agents given with RT may be considered for patients with autoimmune disease. Avoidance of biopsy, tissue manipulation, debridement, or any form of soft-tissue or hard-tissue violation needs to be discussed across the multidisciplinary spectrum to avoid nonhealing lesions shortly after RT.
Journal
|
IFIH1 (Interferon Induced With Helicase C Domain 1)
|
cisplatin • pemetrexed
28d
Infections in psoriatic arthritis: association with treatment. (PubMed, Ther Adv Musculoskelet Dis)
Apart from methotrexate (MTX) and biologics such as tumor necrosis factor (TNFi), interleukin-12/23 (IL-12/23i), and IL-17 inhibitors (IL-17i), traditionally used for the treatment of PsA, recently biologics such as IL-23i and targeted synthetic agents like JAK inhibitors (JAKi) have been introduced in the daily clinical practice for the treatment of this disease...While IL-23i has not been shown to increase the risk for common or opportunistic infections, a well-established association of JAKi with herpes zoster warrants the attention of rheumatologists. In this narrative review, we summarize the infectious complications of available treatment options by drug class in patients with PsA.
Review • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A)
|
methotrexate
29d
LAP2α orchestrates alternative lengthening of telomeres suppression through telomeric heterochromatin regulation with HDAC1: unveiling a potential therapeutic target. (PubMed, Cell Death Dis)
And the use of methotrexate (MTX) can restore the heterochromatin state altered by LAP2α depletion...These results indicate the important role of LAP2α in regulating ALT activity and offer insights into the interplay between lamina-associated proteins and telomeres in maintaining telomere length. Importantly, our findings may help identify a more appropriate target population for the osteosarcoma therapeutic drug, MTX.
Journal
|
HDAC1 (Histone Deacetylase 1)
|
methotrexate
1m
HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease. (PubMed, Am J Gastroenterol)
In a randomized trial of children with CD initiating anti-TNF, 40% were HLA DQ-A1*05 positive, which was associated with a trend toward increased risk of both treatment failure and ADA. These risks were mitigated, but not eliminated, by adding oral methotrexate. HLA DQ-A1*05 is an important biomarker for prognosis and risk stratification.
Journal
|
HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1)
|
methotrexate
1m
New P4 trial
|
methotrexate
1m
The Growth of A549 Cell Line is Inhibited by Pemetrexed Through Up-regulation of hsa-MiR-320a Expression. (PubMed, Adv Biomed Res)
Identifying these MicroRNAs can be helpful in predicting the efficacy of the chemotherapy or introducing it as combination therapy. Our research has been shown that hsa-MiR-320a can serve as a biomarker of PMX efficacy and also has the potential to be used in combination therapy.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • MIR320A (MicroRNA 320a) • VDAC1 (Voltage Dependent Anion Channel 1)
|
BAX expression • miR-320a expression
|
pemetrexed
1m
Phase classification • Metastases
|
cisplatin • pemetrexed
1m
Rheumatoid arthritis with Castleman-like histopathology in lymph nodes: A case report (PubMed, Beijing Da Xue Xue Bao Yi Xue Ban)
She was diagnosed with rheumatoid arthritis with Castleman like histopathology in lymph nodes and was treated with methotrexate and hydroxychloroquine sulfate combined with glucocorticoids. In the first year after sur-gery, the patient' s condition remained stable and there was no growth of lymph nodes in the right axilla. The patient passed away due to severe infection in the second year after the surgery.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
|
methotrexate • hydroxychloroquine
1m
LncRNA-NEAT1 facilitates autophagy to boost pemetrexed resistance in lung adenocarcinoma via the mir-379-3p/HIF1A pathway. (PubMed, Hum Exp Toxicol)
Our study illuminates the role of lncRNA-NEAT1 in LUAD, where it mediates resistance to PEM through the activation of autophagy via the miR-379-3p/HIF1A axis. This work paves the way for new therapeutic strategies for managing PEM resistance in LUAD patients.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • BECN1 (Beclin 1)
|
HIF1A expression
|
pemetrexed
1m
Does Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A Commentary. (PubMed, Rheumatol Ther)
In particular, the lipid paradox associated with RA highlights the complex relationship between RA treatments (MTX, JAKis, tumor necrosis factor (TNF) inhibitors, and interleukin (IL)-6 receptor inhibitors), inflammation, different lipid profiles, and CV risk. In the absence of contraindications and when MTX is tolerated, this commentary suggests the concomitant use of MTX and JAKis as a preferred option for optimizing CV protection in patients with RA.
Journal
|
IL6 (Interleukin 6)
|
methotrexate
1m
Methotrexate promotes the release of granulocyte-macrophage colony-stimulating factor from rheumatoid arthritis fibroblast-like synoviocytes via autocrine interleukin-1 signaling. (PubMed, Arthritis Res Ther)
MTX treatment induces secretion of IL-1 from activated RA-FLS which by autocrine signaling augments their release of GM-CSF. This unexpected effect of MTX might contribute to the persistence of synovitis.
Journal
|
CSF2 (Colony stimulating factor 2) • IL1A (Interleukin 1, alpha) • IL1B (Interleukin 1, beta) • IRAK4 (Interleukin 1 Receptor Associated Kinase 4)
|
CSF2 expression
|
methotrexate • tofacitinib • Kineret (anakinra)
1m
Exploring the effects of pemetrexed on drug resistance mechanisms in human lung adenocarcinoma and its association with PGRMC1. (PubMed, Chem Biol Interact)
This suggests a correlation between PGRMC1 and pemetrexed-induced iron-dependent cell death. Our study contributes to the development of more effective therapeutic strategies to improve the prognosis of patients with lung adenocarcinoma, particularly those facing drug resistance challenges.
Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • PGR expression • KRAS expression
|
pemetrexed
2ms
Rare skin manifestation of juvenile dermatomyositis: peri-orbital oedema and facial swelling. (PubMed, Paediatr Int Child Health)
Although patients presenting with typical clinical features are easy to diagnose, atypical skin findings are challenging for the clinician. In the presence of atypical skin and clinical findings in addition to muscle enzyme elevation, JDM should be considered in the differential diagnosis.Abbreviations: AHCE: asymptomatic hyper-CKemia; AST: aspartate aminotransferase; C: complement; CK: creatine kinase; IVIG: intravenous immunoglobulin; IIM: idiopathic inflammatory myopathy; JDM: juvenile dermatomyositis; LDH: lactate dehydrogenase; MAA: myositis-associated antibodies; MDA5: melanoma differentiation-associated gene 5; MRC: Medical Research Council; MRI: magnetic resonance imaging; MSA: myositis-specific antibodies; MTX: methotrexate NXP2: nuclear matrix protein 2; STIR: short tau inversion recovery; US: ultrasound.
Journal
|
IFIH1 (Interferon Induced With Helicase C Domain 1)
|
methotrexate
2ms
Comparative Study of the Protective Effects of Citral, Thymoquinone, and Silymarin on Methotrexate-induced Cardiotoxicity in Rats. (PubMed, J Pharmacopuncture)
At the end of the study, the rats were anesthetized (ketamine and xylazine) and killed using CO2. The treatment groups, particularly thymoquinone, did not experience any appreciable pathological changes. The thymoquinone was found to have the strongest protective effect against the heart damage caused by MTX.
Preclinical • Journal
|
MB (Myoglobin)
|
methotrexate
2ms
Simultaneous Determination of Methotrexate Concentrations in Human Plasma and Cerebrospinal Fluid Using Two-Dimensional Liquid Chromatography: Applications in Primary Central Nervous System Lymphoma. (PubMed, World J Oncol)
The developed method was useful for therapeutic drug monitoring of MTX and suitable for assessing the risks and benefits of chemotherapy in patients with primary central nervous system lymphoma. Intravenous mannitol did not increase MTX concentration in the CSF of patients.
Journal
|
MMP7 (Matrix metallopeptidase 7)
|
methotrexate • methotrexate IV
2ms
Efficacy of Chinese Herbal Medicine Qing Re Huo Xue in Patients With Rheumatoid Arthritis (clinicaltrials.gov)
P2/3, N=204, Completed, Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Unknown status --> Completed
Trial completion
|
methotrexate
2ms
INTEREST OF REGULAR ASSAYS OF AQUEOUS HUMOR INTERLEUKIN-10 LEVELS IN MONITORING OF VITREORETINAL LYMPHOMA. (PubMed, Retina)
The present study suggested the usefulness of IL-10 in the prognosis of VRL. This study showed a relation between IL-10 in AH and tumoral activity, and for the first time with disease relapse.
Retrospective data • Journal
|
IL10 (Interleukin 10)
|
IL10 elevation
|
methotrexate
2ms
A randomized controlled trial of csDMARDs combined with Tripterygium glycoside tablets in the treatment of rheumatoid arthritis (ChiCTR2400088173)
P=N/A, N=188, Not yet recruiting, Dongzhimen Hospital, Beijing University of Chinese Medicine; Dongzhimen Hospital, Beijing University of Chinese Medicine
New trial
|
IL6 (Interleukin 6)
|
methotrexate • hydroxychloroquine • leflunomide
2ms
Can Alpha-Pinene Prevent Methotrexate-Induced Cardiac and Hepatic Damage? (PubMed, Physiol Res)
Considering the importance of MTX in cancer treatment, AP appears to have highly promising potential as a cardioprotective and hepatoprotective agent in anti-tumoral therapy. Key words: MDA, GSH, Caspase-3, p53, Oxidative stress, Apoptosis.
Journal
|
CASP3 (Caspase 3)
|
methotrexate
2ms
Methotrexate Toxicity-Induced Pancytopenia and Mucocutaneous Ulcerations in Psoriasis. (PubMed, Cureus)
Treatment included intravenous leucovorin, blood and platelet transfusions, and granulocyte-macrophage colony-stimulating factor (GM-CSF). Despite initial critical presentation, the patient showed significant improvement, with recovery of blood counts and resolution of symptoms. He was discharged with stable hemoglobin, platelet, and white blood cell counts.
Journal
|
CSF2 (Colony stimulating factor 2)
|
methotrexate • leucovorin calcium
3ms
Development and Evaluation of Methotrexate and Baicalin-Loaded Nanolipid Carriers for Psoriasis Treatment. (PubMed, Turk J Pharm Sci)
MTX-BL NLCs were inhibited the expression of inflammatory cytokines (tumor necrosis factor-alpha, and interleukin-17) . It can be concluded that newer targeting strategies for NLCs for dual-drug delivery of nano-lipid carriers could be administered topically for the treatment of psoriasis.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A)
|
methotrexate
3ms
Chinese Herbal Compound Xiaoliu Pingyi Recipe Inhibits the Growth of Lung Adenocarcinoma by Regulating the Tumor Vascular Microenvironment. (PubMed, Integr Cancer Ther)
In the in vivo study, a C57BL/6J mouse model of lung adenocarcinoma (LUAD) allografts was established, and various interventions were administered for 14 days (Model group: administered normal saline via oral gavage; Pemetrexed (PEM) group: intraperitoneally injected with a solution of pemetrexed, once every 3d; XLPYR group: administered XLPYR via oral gavage; Combination (COMBI) group: received XLPYR via oral gavage simultaneously with intraperitoneal injection of pemetrexed solution)...It suppressed LUAD cell proliferation, migration, and invasion, while reducing VEGF concentration in the cell supernatant. The regulatory mechanism may involve inhibiting PI3K/Akt protein phosphorylation and downregulating angiogenesis-related factors, such as HIF-1α, VEGF, and Ang-2.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
HIF1A expression • VEGFA expression
|
pemetrexed
3ms
Efficacy and safety of methotrexate plus hydroxychloroquine combination therapy vs. methotrexate monotherapy in the treatment of rheumatoid arthritis: A randomized controlled clinical trial. (PubMed, Int J Rheum Dis)
In our study, both the MTX + HCQ combination therapy and MTX monotherapy demonstrated improvements in symptoms, conditions and quality of life for patients with RA. Notably, the combination therapy could achieve better outcomes across all indices compared to MTX monotherapy, highlighting its potential as the optimal first-line treatment for RA.
Clinical • Journal • Combination therapy
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CRP (C-reactive protein)
|
methotrexate • hydroxychloroquine
3ms
Pirfenidone targeted mechanisms for alleviating methotrexate-induced testiculopathy in Wistar rats. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
In addition, antifibrotic effects, anti-caspase-3, and PCNA enhancement activity were recorded. PFD exhibited a protective potential and mitigated the MTX-induced testiculopathy via suppression of testicular oxidative stress, inflammation, fibrosis, and apoptosis and retaining the testicular proliferative efficacy as confirmed by histological, immunohistochemical, and biochemical methods.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • PCNA (Proliferating cell nuclear antigen) • IL1B (Interleukin 1, beta)
|
methotrexate